



(11) **EP 2 082 738 A8**

(12) **CORRECTED EUROPEAN PATENT APPLICATION**

(15) Correction information:
Corrected version no 1 (W1 A1)
Corrections, see
Bibliography INID code(s) 84

(51) Int Cl.:
A61K 31/19 (2006.01) A61P 11/06 (2006.01)

(48) Corrigendum issued on:
23.06.2010 Bulletin 2010/25

(43) Date of publication:
29.07.2009 Bulletin 2009/31

(21) Application number: **09156851.9**

(22) Date of filing: **19.12.2006**

(84) Designated Contracting States:
DE ES GB IE IT TR

(30) Priority: **19.12.2005 US 752253 P**

(62) Document number(s) of the earlier application(s) in
accordance with Art. 76 EPC:
06845745.6 / 1 968 564

(71) Applicant: **ABBOTT LABORATORIES**
Abbott Park IL 60064-3500 (US)

(72) Inventors:
• **Thomas, Debra, L.**
Columbus, OH 43221 (US)

• **Mukerji, Pradip**
Columbus, OH 43230 (US)

(74) Representative: **Modiano, Micaela Nadia**
Modiano Josif Pisanty & Staub Ltd
Thierschstrasse 11
80538 München (DE)


Remarks:

This application was filed on 31-03-2009 as a
divisional application to the application mentioned
under INID code 62.

(54) **Use of beta-hydroxy-beta-methylbutyrate to treat asthma**

(57) Disclosed are methods of treating an individual having asthma wherein the method comprises administering to the individual an amount of β -hydroxy- β -methylbutyrate (HMB) effective to modulate or otherwise cause an increase in the ratio of type (1) to type (2) cytokines, including an increase in the ratio of type (1) to type (2) cytokines without a corresponding increase in type (2) cytokine levels. The methods of the present invention are based upon the discovery that HMB modulates cytokine production, most typically by increasing type (1) cytokines without a corresponding increase in type (2) cytokines.

Fig. 5
Effect of HMB on ratio of IFN γ to type 2 cytokines: 24 hr
CD3/CD28 stimulation, n=10



EP 2 082 738 A8